Skip to Content

'
Charles A. Conrad, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Conrad divides his time between active patient care within the clinic and laboratory investigations and has participated in numerous clinical trials evaluating agents for primary brain tumor therapy.  His focus has been to identify similarities of tumor biology and clinical progression in an attempt to develop new treatment agents that may be effective against primary brain tumors.  His primary areas of concern are to improve treatment strategies for patients with high-grade glial neoplasms and both his clinic and research efforts are directed towards these areas. He has four primary areas of focus within his laboratory concerning: (1) the development of oncolytic adenoviral therapies in conjunction with Dr. Juan Fueyo, Associate Professor in the Department of Neuro-Oncology; (2) evaluating the effectiveness of using newer signal transduction inhibitors in mouse brain tumor models; (3) novel in-house drug development with collaborations with researchers in the Department in Experimental Therapeutics, and  (4) developing an understanding of the biology of galactins in gliomagenesis and progression.

 

 

Education & Training

Degree-Granting Education

1988 University of Texas Medical School, Houston, TX, MD, Medicine
1984 Texas A&M University, College Station, TX, BS, Microbiology

Postgraduate Training

7/1992-6/1994 Clinical Fellow, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1989-6/1992 Resident, Neurology, The University of Texas Medical School at Houston, Houston, TX
7/1988-6/1989 Intern, Internal Medicine, the University of Texas Medical School at Houston, Houston, TX

Board Certifications

2/2012 American Board of Psychiatry and Neurology

Experience/Service

Academic Appointments

Associate Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 4/2000-8/2008
Faculty Associate, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas, M.D., Anderson Cancer Center, Houston, TX, 7/1994-8/1995

Administrative Appointments/Responsibilities

Director of Clinical Operations, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2009-present
Member, Translational Research Focus Group of the Clinical Research Subcommittee for the Brain Tumor Center, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, 1/2002-present
Member, Executive Committee for the Brain Tumor Center, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, 1/2001-present
Medical Director, Brain and Spine Center, Division of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, 9/2000-5/2005
Chair, Brain and Spine Operations Committee, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, 9/2000-5/2005

Institutional Committee Activities

Chairman, Neurophysiology Search Committee, 6/2011-present
Appointed Member, Research Laboratory Space Subcommittee of the Research Council, 2/2010-2/2013
Appointed Member, Clinical Effectiveness Subcommittee, 9/2007-9/2008
Appointed Member, Faculty Senate, 9/2006-9/2007
Appointed Associate Member, Institutional Animal Care and Use Committee, 1/2005-1/2006

Honors and Awards

2013-2014 Best Doctors, Best Doctors in America
2012-2013 Waun Ki Hong Award for Excellence in Team Science, UT MD Anderson Cancer Center
2011-2012 Best Doctors, Best Doctors in America
2007-2008 Best Doctors, Best Doctors in America
2005-2006 Multi-Year Appointment Award, M.D. Anderson Cancer Center
1993-1994 Fellowship Award, American Cancer Society
1992-1993 Fellowship Award, American Cancer Society

Professional Memberships

American Academy of Neurology
Member, 1/1994-present
American Association for Cancer Research (AACR)
Member, 1/1994-present
American Medical Association
Member, 1/1994-present
American Society of Clinical Oncology (ASCO)
Member, 1/1994-present
Harris County Medical Society
Member, 1/1994-present
North American Brain Tumor Consortium
Member, 4/2000-present
Society for Neuro-Oncology
Member, 1/1995-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Gomez-Manzano C, GabrusiewiczK, Liu D, Cortes N, Hossain MB, Conrad CA, Aldape K, Fuller G, Marini F, Alonso MM, Gilbert M, Fueyo-Margareto J. Anti-VEGF therapy-induced glioma invasion is associated with accumulation of Tie2-Expressing Monocytes. Oncotarget. In Press.
2. Penas-Prado M, Woo S, Lagrone L, Fisch MJ, Groves MD, degroot JF, Puduvalli V, Colman H, Conrad CA, Loghin ME, Hsu SH, Gonzalez J, Mahajan A, Yung WKA, Chang E, ; Levin VA, Volas-Redd G, Giglio P, Salacz, ME, Floyd JD, Aldape KD. Randomized phase II adjuvant factorial study of dose-dense Temozolomide alone and in combination with Isotretinoin, Celecoxib, and/or Thalidomide for glioblastoma. Neuro-Oncology. In Press.
3. Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, Degroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol. e-Pub 5/2014. PMID: 24803001.
4. Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, Fuller GN, Marini FC, Alonso MM, Idoate MA, Gilbert MR, Fueyo J, Gomez-Manzano C. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget 5(8):2208-20, 4/2014. PMID: 24809734.
5. Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and glial brain tumors. Neuro Oncol. e-Pub 3/2014. PMID: 24615863.
6. Emmett MR, Kroes RA, Moskal JR, Conrad CA, Priebe W, Laezza F, Meyer-Baese A, Nilsson CL. Integrative biological analysis for neuropsychopharmacology. Neuropsychopharmacology 39(1):5-23, 1/2014. e-Pub 6/2013. PMCID: PMC3857644.
7. Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer 119(15):2747-53, 8/2013. e-Pub 4/2013. PMID: 23633392.
8. Fokt I, Skora S, Conrad C, Madden T, Emmett M, Priebe W. D-Glucose and D-mannose-based metabolic probes. Part 3. Synthesis of specifically deuterated D-glucose, D-mannose and 2-deoxy-D-glucose. Carbohydr Res 368:111-9, 3/2013. e-Pub 12/2012. PMID: 23376241.
9. Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118(14):3599-606, 7/15/2012. e-Pub 11/15/2011. PMID: 22086614.
10. Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol 69(6):1507-18, 6/2012. e-Pub 3/7/2012. PMID: 22392572.
11. Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol 107(3):487-501, 5/2012. e-Pub 1/17/2012. PMID: 22249692.
12. Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol 69(1):281-7, 1/2012. e-Pub 10/9/2011. PMID: 21984222.
13. He H, Emmett MR, Nilsson CL, Conrad CA, Marshall AG. High Mass accuracy and resolution facilitate identification of glycosphingolipids and phospholipids. International Journal of Mass Spectrometry 305(2-3):116-119, 8/2011.
14. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. e-Pub 4/2011. PMID: 21480200.
15. Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Alfred Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Nebiyou Bekele B, Qiao W, Levin VA. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol 102(2):273-280, 4/2011. e-Pub 7/2010. PMID: 20652724.
16. Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A Phase I Factorial Design Study of Dose-Dense Temozolomide Alone and in Combination with Thalidomide, Isotretinoin, and/or Celecoxib as Post-chemoradiation Adjuvant Therapy for Newly Diagnosed Glioblastoma. Neuro Oncol. e-Pub 8/2010. PMID: 20729242.
17. He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR, Ji Y, Colman H, Priebe W, Lang FF, Conrad CA. Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. J Proteome Res 9(5):2098-2108, 3/2010. PMID: 20199106.
18. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12(3):233-42, 3/2010. e-Pub 1/2010. PMID: 20167811.
19. Nilsson CL, Dillon R, Devakumar A, Shi SD, Greig M, Rogers JC, Krastins B, Rosenblatt M, Kilmer G, Major M, Kaboord BJ, Sarracino D, Rezai T, Prakash A, Lopez M, Ji Y, Priebe W, Lang FF, Colman H, Conrad CA. Quantitative Phosphoproteomic Analysis of the STAT3/IL-6/HIF1alpha Signaling Network: An Initial Study in GSC11 Glioblastoma Stem Cells. J Proteome Res 9(1):430-43, 1/2010. e-Pub 11/2009. PMID: 19899826.
20. Görke R, Meyer-Bäse A, Wagner D, He H, Emmett MR, Conrad CA. Determining and interpreting correlations in lipidomic networks found in glioblastoma cells. BMC Syst Biol 4:126, 2010. PMID: 20819237.
21. Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Yung WKA. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 101(4):615-620, 8/2009. PMID: 19672263.
22. He H, Nilsson CL, Emmett MR, Ji Y, Marshall AG, Kroes RA, Moskal JR, Colman H, Lang FF, Conrad CA. Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, Irinotecan. Glycoconj J. e-Pub 6/2009. PMID: 19557511.
23. Hess KR, Puduvalli V, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WKA, Liu TJ. Biomarkers of disease: Cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol, 3/2009. PMID: 19267183.
24. Jiang H, White EJ, Conrad C, Gomez-Manzano C, Fueyo J. Autophagy pathways in glioblastoma. Methods Enzymol 453:273-86, 1/2009. PMID: 19216911.
25. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. VEGF trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940-5, 12/2008. e-Pub 8/2008. PMID: 18708344.
26. Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo J. Oncolytic Adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16(3):256-265, 10/2008. PMID: 18927600.
27. Conrad C, Gupta R, Mohan H, Niess H, Bruns CJ, Kopp R, von Luettichau I, Guba M, Heeschen C, Jauch KW, Huss R, Nelson PJ. Genetically engineered stem cells for therapeutic gene delivery. Curr Gene Ther 7(4):249-60, 8/2007. PMID: 17969558.
28. Conrad C, Ischenko I, Köhl G, Wiegand U, Guba M, Yezhelyev M, Ryan AJ, Barge A, Geissler EK, Wedge SR, Jauch KW, Bruns CJ. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs 18(5):569-79, 6/2007. PMID: 17414626.
29. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, Deangelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81(3):271-7, 2/2007. e-Pub 9/2006. PMID: 17031561.
30. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 80(1):83-90, 10/2006. e-Pub 4/2006. PMID: 16639492.
31. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L. Schiff E, Lieberman F, Fine HA, Mehta M, robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of Imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor consortium Study 99-08. Clin Cancer Res 12(16):4899-4907, 8/2006. PMID: 16914578.
32. Guo W, Zhu H, Zhang L, Davis J, Teraishi F, Roth JA, Stephens C, Fueyo J, Jiang H, Conrad C, Fang B. Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther 13(1):82-90, 2006. PMCID: PMC1343537.
33. Jiang H, Alemany R, Gomez-Manzano C, Medrano DR, Lemoine MG, Olson MV, Alonso MM, Lee OH, Conrad CC, Yung WK, Fueyo J. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia 7(8):723-9, 8/2005. PMCID: PMC1501891.
34. Chang SM, Wen P, Cloughesy T, Greenberg H, Schieff D, Conrad C, Fink K Robins HI, deAngelis L, Raizer J, Hess K. Aldape K, Lamborn KR, Kuhn J. Dancey J, Prados MD. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23(4):357-361, 8/2005. PMID: 16012795.
35. Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12(3):284-94, 3/2005. PMID: 15650766.
36. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4(1):101-12, 2005. PMID: 15657358.
37. Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN, Lin E, Conrad CC, Yung WK, Fueyo J. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7(1):48-56, 2005. PMCID: PMC1490320.
38. Heimberger AB, Wang E, McGary EC, Hess KR, Henry VK, Shono T, Cohen Z, Gumin J, Sawaya R, Conrad CA, Lang FF. Mechanisms of action of rapamycin in gliomas. Neuro Oncol 7(1):1-11, 2005. PMCID: PMC1871627.
39. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 22(4):427-35, 11/2004. PMID: 15292713.
40. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22(21):4282-9, 11/2004. PMID: 15514370.
41. Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 23(10):1821-8, 3/2004. PMID: 15014451.
42. Cerrato JA, Khan T, Koul D, Lang FF, Conrad CA, Yung WK, Liu TJ. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas. Int J Oncol 24(2):409-17, 2/2004. PMID: 14719118.
43. Colman H, Sai K. Wang S, Popoff S, Aldape KD., Lang FF, Conrad CA, Madden T. Yung A, Priebe W. Effect of a small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells. J Clin Oncol 26(May 20 Supplement), 5/2003.
44. Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci 8:d577-88, 5/2003. PMID: 12700119.
45. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9):652-60, 5/2003. PMID: 12734316.
46. Chen Y, Ji YJ, Conrad C. Expression of ssDNA in mammalian cells. Biotechniques 34(1):167-71, 2003. PMID: 12545555.
47. Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 53(1):109-17, 2003. PMID: 12509854.
48. Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro Oncol 4(4):268-77, 10/2002. PMCID: PMC1920662.
49. Conrad CA. Chemotherapy for metastatic tumors to the central nervous system. Curr Oncol Rep 3(6):490-4, 11/2001. PMID: 11595117.
50. Fueyo, J, Gomez-Manzano C, Fuller NG, Khan A, Lemoine MG, Lang FF, Conrad C, Yung WKA. Treatment of gliomas xenografts with D24 oncolytic adenovirus: A pathological study. Neurology 56:A407, 2001.
51. Conrad CA, Milosavljevic VP, Yung WK. Advances in chemotherapy for brain tumors. Neurol Clin 13(4):795-812, 11/1995. PMID: 8583997.
52. Conrad, CA, Steck PA. Protein tyrosine phosphatases in signal transduction. Cancer Bulletin 47 45:125-130, 1995.
53. Conrad CA, Stearns GW, 3rd, Prater WE, Rheiner JA, Johnson JR. Characterization of a glpK transducing phage. Mol Gen Genet 193(2):376-8, 1984. PMID: 6319974.
Other Articles
1. Jiang H, Fueyo J, Merville SD, Yung WKA, Conrad CA, Lang FF. Virus targets brain tumor stem cells. Journal of the National Cancer Institute 18, 9/2007. e-Pub 9/2007.

Abstracts

1. Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung WKA, degroot J. Clinical and demographic features of adult patients with glioblastoma (GBM) participating on clinical trial protocols at the University of Texas MD Anderson Cancer Center (MDACC). Neuro-Oncology. In: Proceedings from the 18th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, (SNO) San Francisco, CA, November 21 – 24, 2013 15(3):iii98 (#NO-002), 11/2013.
2. Sulman EP, Wang Q, Mostovenko E, Liu H, Lichti CF, Shavkunov A, Kroes RA, Moskal JR, Conrad CA, Lang FF, Emmett MR, Nilsson CL. Integration of gene and protein expression in thirty-seven glioma stem cell lines. Neuro-Oncology. In: Proceedings from the 18th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, (SNO) San Francisco, CA, November 21 – 24, 2013 15(3):iii212 (#SC-029), 11/2013.
3. Jiang H, Klein SR, Piya S, Vence L, Yung WKA, Sawaya R, Heimberger A, Conrad C, Lang, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGD infection activates T-cell immune response against glioma cells. Neuro-Oncology. In: Proceedings from the 18th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, (SNO) San Francisco, CA, November 21 – 24, 2013 15(3):iii63 (#IR-009), 11/2013.
4. Conrad C, Yung WKA, deGroot J, Gilbert M,Loghin M, Penas-Prado M, Tremont I, Silberman S, Picker D. Phase 1 trial of bevacizumab plus TPI 287 in adults with recurrent glioblastoma (GBM). Neuro-Oncology. In: Proceedings from the 18th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, (SNO) San Francisco, CA, November 21 – 24, 2013 15(3):iii106 (#NO-033), 11/2013.
5. Cortes-Santiago N, Gabrusiewicz K, Liu D, Hossain MB, Gumin J, Fan X, Conrad C, Aldape K, Gilbert M, Raghunathan A, Yung WKA, Fueyo, Gomez-Manzano C. Insights on the role of microenvironment in the recurrence of malignant gliomas to anti-vascular endothelial growth factor therapy: Opportunities for new combined therapies. Neuro-Oncology. In: Proceedings from the 17th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, (SNO) Washington, DC, November 15-18, 2012 14(Supplement 6):vi4 (#AI-18), 11/2012.
6. Yust-Katz S, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WKA, Gilbert MR. Phase 1/1B study of Lonafarnib and Temozolomide in patients with recurrent or Temozolomide refractory glioblastoma. Neuro-Oncology. In: Proceedings from the 17th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, (SNO) Washington, DC, November 15-18, 2012 14(Supplement 6):vi68 (#NO-19), 11/2012.
7. Nilsson CL, Sulman E, Liu H, Wild C, Licht CF, Emmett MR, Lang FF, Conrad C. Protein expression in glioma-derived stem-like cells correlated to gene expression data and patient outcomes. Neuro-Oncology. In: Proceedings from the 17th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, (SNO) Washington, DC, November 15-18, 2012 14(Supplement 6):vi96 (#OM-27), 11/2012.
8. Colman H, Gilbert M, Yung WKA, Aldape K, deGroot J, Conrad C, Levin V, Groves M, Loghin M, Pelloski C, Puduvalli V. A phase I study of Sorafen1B with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii61 (#NO-89), 11/2011.
9. Groves MD, DeGroot J, Loghin M, Conrad C, Hess K, Ictech S, Hunter K, Yung WKA. A phase I study of Temozolomide and Intrathecal Liposomal Cytarabine in patients with neuroplastic meningitis. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii43 (#NO-11), 11/2011.
10. Bankson JA, SandulacheV, Merritt M, Elliott A, Chen Y, Schellingerhout D, Lai SY, Conrad C, Hazle JD. Dynamic Spectroscopy and Modeling of Response to 2-Deoxyglucose using Hyperpolarized [1-13C]-Pyruvate. In: Proceedings of the Cancer Prevention Research Institute of Texas (CPRIT) meeting, Austin TX, November 15-17, 2011, 11/2011.
11. Mammoser AG, Shah K, Conrad CA. Increased risk of cerebral atrophy with prolonged Bevacizumab administration. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii57 (#NO-72), 11/2011.
12. Conrad CA, Xu W, Sheng X, Nilsson C, Marshall AG, Emmett MR. Novel phosphorylation site in glioma expressed galectin-1 modulates invasive phenotype. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii21 (#CB-50), 11/2011.
13. Puduvalli VK, Penas-Prado M, Hess KR, Hunter K, Ictech S, Groves MD, Gilbert, Liu V, Conrad CA, degroot J, Loghin ME, Colman H, Levin VA, Yung WKA. Phase I/II adaptive randomized trial of Vorinostat, Isotretinoin and Carboplatin in adults with recurrent glioblastoma multiforme - results of the phase I arm. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii49 (#NO-36), 11/2011.
14. Priebe W, Emmett M, Ji Y, Fokt I, Skora S, Conrad CA, Wang X, Marshall HG. 2-DG inhibits of N-glycosylation in glioblastoma-derived cancer stem cells. In: Proceedings of the Annual Meeting of the American Association for Cancer Research, 2011, Apr 2-6, 2011; Orlando, FL (#2304), 4/2011.

Book Chapters

1. Hong J, White EJ, Conrad C, Gomez-Manzano C, Fueyo J. Autophagy Pathways in Glioblastoma. In: Methods in Enzymology. 453. Ed(s) Daniel J. Klionsky. Elsevier Inc. Academic Press: Burlington, 273-286, 2009. ISBN: 978-0-12-274936-9.
2. Conrad CA, Heimberger AB. Innovative Treatment Strategies for High Grade Glioma. In: Tumors of the Brain and Spine, M.D. Anderson Cancer Care Series, 1. Ed(s) F Demonte, MR Gilbert, A Mahajan, IE McCutcheon. Springer: Houston, Texas, 171-187, 2007. ISBN: 13:978-0387-29201-4.
3. Conrad CA, Yung WKA. Systemic chemotherapy for metastatic tumors of the central nervous system. In: Brain Tumors, 1. Ed(s) Francis Ali-Osman (ed). Humana Press: USA, 267-278, 2005.
4. Conrad CA, Pro B, Prabbu S, McCutcheon IE, Demonte F. Primary Brain Tumors. In: Atlas of Cancer, 1. Ed(s) Maurie Markman. Lippincott Williams & Wilkins,: Philadelphia, PA, 561-593, 2002. ISBN: 0-7817-4280-3.

Grant & Contract Support

Title: SPORE in Brain Cancer - Project 4: Modulation of cognitive function and outcomes in glioblastoma patients
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Frederick Lang
Duration: 9/1/2013 - 8/31/2018
 
Title: SPORE in Brain Tumor - Co-Leader - Project 4: Targeting Malignant gliomas with a Novel Inhibitor of the STAT3 Pathway
Funding Source: NIH/NCI
Role: Co-Program Leader
Principal Investigator: WKA Yung
Duration: 9/1/2013 - 8/31/2018
 
Title: A phase I/1b, open-label study in patients with recurrent glioblastoma to assess the safety and tolerability of macitentan in combination with dose-dense temozolomide
Funding Source: Actelion Clinical Research Inc
Role: Principal Investigator
Duration: 12/11/2011 - 12/31/2013
 
Title: A phase 2 CT open-label study of the efficacy of TPI-287 in patients with glioblastoma multiforme that has recurred or progressed following prior therapy with radiation plus temozolomide
Funding Source: Archer Pharmaceuticals
Role: Principal Investigator
Duration: 4/9/2010 - 4/1/2014
 
Title: A phase II open-label study of the efficacy of TPI-287 in patients with glioblastoma multiforme that has recurred or progressed following prior therapy with radiation plus Temozolomide
Funding Source: Archer Pharmaceuticals
Role: Principal Investigator
Duration: 4/9/2010 - 4/30/2012
 
Title: SPORE in Brain Cancer - Core E - Animal Core
Funding Source: NIH/NCI
Role: Co-Director
Principal Investigator: W.K.Alfred Yung, M.D.
Duration: 9/1/2008 - 8/31/2013
 
Title: Stat3 Drug Development for High Grade Gliomas, N/A
Funding Source: UTMDACC Development Office Gifts
Role: Principal Investigator
Duration: 11/13/2007 - 11/20/2012
 
Title: Project 4: Development of glycolytic inhibitors for patients with recurrent ependymomas, N/A
Funding Source: Collaborative Ependymoma Research Network (CERN)
Role: Project Leader
Principal Investigator: Waldemar Priebe
Duration: 7/20/2007 - 7/19/2015

Last updated: 7/24/2014